Welcome to our dedicated page for Hca Healthcare SEC filings (Ticker: HCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HCA Healthcare filings document a NYSE-listed healthcare services company whose common stock is registered under Section 12(b) and whose wholly owned subsidiary, HCA Inc., issues senior unsecured notes guaranteed by the parent. Recent 8-K reports record quarterly operating results, dividends, share repurchase authorization, commercial paper and debt refinancing activity, and indenture supplements for senior notes.
Proxy and annual-meeting disclosures cover director elections, shareholder voting results, board matters, executive compensation, and performance award programs linked to EBITDA and quality measures. Registration and offering-related filings describe shelf registration use, prospectus supplements, note terms, guarantees, trustee arrangements and capital-structure disclosures for HCA's healthcare services operations.
HCA Healthcare EVP and CFO Mike A. Marks received a new equity award in the form of stock appreciation rights. On January 29, 2026, he was granted 11,945 stock appreciation rights tied to HCA common stock at an exercise price of $482.53 per share. These rights vest in four equal annual installments beginning January 29, 2027 and expire January 29, 2036. Following this grant, he beneficially holds 11,945 derivative securities directly.
HCA Healthcare CEO Samuel N. Hazen reported several equity compensation moves. On January 29, 2026, he received 55,846 stock appreciation rights with an exercise price of $482.53 per share, which vest in four equal annual installments beginning on January 29, 2027.
On January 30, 2026, Hazen exercised 84,360 stock appreciation rights, acquiring 84,360 shares of common stock at $81.96 per share. To cover tax obligations, 41,483 shares were surrendered at a value of $488.27 per share, leaving 75,153 shares of common stock held directly. He also reports additional indirect ownership through several trusts and an LP.
HCA Healthcare EVP and COO Jon M. Foster reported a grant of 11,945 stock appreciation rights (SARs) on HCA common stock at an exercise price of $482.53 per share. These SARs become exercisable in four equal annual installments beginning on January 29, 2027 and expire on January 29, 2036. The filing also lists indirect holdings of HCA common stock held through several trusts, including JMF Trust, LCF Trust, JMF Family Trust, and a 2025 GRAT.
HCA Healthcare EVP and Chief Clinical Officer Michael S. Cuffe received a grant of 8,067 stock appreciation rights on January 29, 2026. Each right has an exercise price of $482.53 and is settled in HCA common stock.
The stock appreciation rights vest in four equal annual installments beginning on January 29, 2027, and expire on January 29, 2036. Following this grant, Cuffe beneficially owns 8,067 derivative securities directly related to HCA common stock.
HCA Healthcare SVP & Chief Human Resources Officer Jennifer Berres received a grant of 6,206 stock appreciation rights on common stock. The rights have an exercise price of $482.53 and were awarded on January 29, 2026. All 6,206 derivative securities are held as direct ownership.
The stock appreciation rights vest in four equal annual installments beginning on January 29, 2027, and expire on January 29, 2036. This grant represents equity-based compensation that ties part of the executive’s potential future value to HCA Healthcare’s share price performance over time.
HCA Healthcare, Inc. reported that it issued a press release with its results of operations for the fourth quarter and full year ended December 31, 2025, made available as Exhibit 99.1.
The company also announced that its Board of Directors authorized an additional share repurchase program for up to $10 billion of its outstanding common stock, with repurchases to be made from time to time in the open market, through privately negotiated transactions, or otherwise, in accordance with applicable securities laws.
In addition, the Board declared a quarterly cash dividend of $0.78 per share on HCA common stock, payable on March 31, 2026 to stockholders of record at the close of business on March 17, 2026. These capital return actions highlight ongoing distributions to shareholders through both repurchases and cash dividends.
HCA Healthcare's CEO and director reported an insider transaction in common stock. On 11/14/2025, the insider made a gift (code G) of 14,830 shares at a reported price of $0, reducing directly held shares to 32,276.
The insider also reports indirect ownership of HCA common stock through several entities, including 14,979 shares held by HD Trust, 16,731 by 2023 GST Trust, 93,088 by 2023 Trust, 178,289 by 2024 GRAT, 200,000 by 2025 GRAT, and 813,320 shares held by an LP. No derivative securities are reported in the derivative securities table.
HCA Healthcare (HCA) executive reports equity transactions. On 11/03/2025, the EVP & Chief Legal & Admin Off. exercised stock appreciation rights for 13,170 shares at $236.61 (code M), and disposed of 9,278 shares at $461.56 (code F), leaving 7,379 shares directly held after those transactions. On 11/05/2025, the executive sold 3,892 shares at $473.79 (code S), with 3,487 shares directly held afterward. The filing also lists 2,111 shares held indirectly by a 2024 GRAT and 26 shares held indirectly by a managed account, as described in the footnotes.
HCA Healthcare (HCA) Form 4: the company’s EVP and CFO reported charitable gifts of common stock. The filing lists a gift of 165 shares on 11/03/2025 and another 165 shares on 11/05/2025 (Transaction Code G), both at a reported price of $0.
Following these transactions, the filing shows 43,240 shares held indirectly by the MAM 2020 Trust and 26,500 shares held indirectly by the LAM 2020 Trust. One line reflects direct holdings of 0 shares after the 11/05/2025 entry.
Form 4 disclosures track insider ownership changes; gifts (code G) are non-cash transfers and do not indicate open‑market sales.
HCA Healthcare (HCA) filed a Form 144 notice for the proposed sale of 3,892 shares of common stock. The filing lists an aggregate market value of $1,843,990.68 for the shares, with an approximate sale date of November 5, 2025. The broker is Merrill Lynch, and the shares are listed on the NYSE.
The shares were acquired on November 3, 2025 through the exercise of a stock appreciation right, noted as a compensatory payment. Shares outstanding were 228,193,900.